Recruiting

Glossopharyngeal Blockade

Sponsor:

Royal Victoria Hospital, Canada

Code:

NCT01791439

Conditions

Gagging

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

lidocaine

placebo

Study Details

Brief summary:

The investigators wish to determine if application of 2% lidocaine soaked gauze to the peritonsillar pillars will decrease the amount of gagging caused by awake videolaryngocope assisted tracheal intubation in the morbidly obese.

Conditions

Gagging

Study ID

NCT01791439

Start date

Jan, 2013

Status verified date

Feb, 2013

Primary completion date

Apr, 2013

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • morbid obese patients scheduled for bariatric surgery, with a planned awake intubation.

Exclusion Criteria:

  • inability to communicate in English or french
  • allergies to any study drugs
  • any patient with an American society of anesthesiologists score of 4 or more

Study Design

Enrollment

24 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Interventions and Outcome Measures

Arms

experimental: Lidocaine

Patients in this arm will have gauze soaked with lidocaine applied to the peritonsillar pillars.

placebo comparator: Saline

Application of saline to the glossopharyngeal nerve.

Interventions

lidocaine

Application of lidocaine to the glossopharyngeal nerve.

placebo

Primary outcome measure

  • Gagging [ Time Frame: 2 minutes ]

Central Contacts and Locations

Central contacts

Albert Moore, md

5149341934moore_albert@hotmail.com

Locations

Royal Victoria Hospital

Recruiting

Montreal, Quebec, Canada, H3A1A1

Contacts

Albert Moore, MD

5149341934moore_albert@hotmail.com

More Information

Sponsor

Royal Victoria Hospital, Canada

Last update posted

Feb 15, 2013

Last verified

Feb, 2013

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Royal Victoria Hospital, Canada on 2013-02-15.